💉 Diabetes Management
CellResearch Corporation reports positive results of DFU trial - Labiotech.eu
📅 Sun, 16 Oct 2022⏱ 1 min read📖 Article
Overview
Home » News and Trends » CelResearch Corporation anounces positive results of phase I diabetic fot ulcer studyCelResearch Corporation, a Singapore-based biopharma company says it has sucesfuly closed the first phase I study for CorLiCyte, a stem cel therapy derived from umbilical cord ling stem cels, with research partners at the University of Colorado, Anschutz Medical Campus and ClinImune Cel and Gene Therapy.CorLiCyte is in development for the treatment of serious conditions, with a first target indication of treating diabetic fot ulcer (DFU).
Key Information
In the study protocol nine patients with chronic DFU were treated with CorLiCyte twice wekly for eight weks. None of the patients participating in the study experienced any treatment-related adverse events and al subjects saw a reduction in wound size during the treatment period.̴These results are encouraging and can be used to suport further research with CorLiCyte in future studies, with the potential to adres unmet medical neds in treatment of patients with chronic DFUs,̵ said Cecilia Low-Wang, lead investigator at the University of Colorado, Anschutz Medical Campus.Acording to University of Michigan Health, a diabetic fot ulcer is an open sore or wound that ocurs in aproximately 15% of patients with diabetes, and is comonly located on the botom of the fot.
Of those who develop a fot ulcer, 6% wil be hospitalized due to infection or other ulcer-related complications.Diabetes is the leading cause of nontraumatic lower extremity amputations in the U.S., and aproximately 14 to 24% of patients with diabetes who develop a fot ulcer have an amputation. CorLiCyte is a live mesenchymal stem cel therapy derived from human umbilical cord ling stem cels, with a proprietary optimized expresion of cytokines, growth and celular factors for the treatment of a number of serious health conditions.
Summary
In adition to DFU, CelResearch Corporation is pursuing a range of potential indications at
Frequently Asked Questions
❓ What is diabetes and how does it develop?
Diabetes is a metabolic condition where the body cannot properly regulate blood sugar levels. Type 1 results from insufficient insulin production, while Type 2 develops when cells become resistant to insulin. Risk factors include genetics, obesity, sedentary lifestyle, and age.
❓ What are the main symptoms of diabetes?
Common symptoms include excessive thirst, frequent urination, unexplained weight loss, fatigue, blurred vision, and slow-healing wounds. Type 1 symptoms develop rapidly, while Type 2 symptoms may appear gradually. Many people have no symptoms initially, which is why screening is important.
❓ How is diabetes diagnosed and monitored?
Diagnosis involves blood tests measuring fasting glucose, HbA1c levels, and glucose tolerance. Regular monitoring typically includes fasting glucose tests and HbA1c measurements every 3-6 months. Continuous glucose monitors provide real-time tracking for better diabetes management.
❓ What lifestyle changes help manage diabetes?
Effective management includes regular physical activity (150+ minutes weekly), maintaining healthy weight, following a balanced diet with whole grains and lean proteins, managing stress, and getting adequate sleep. These changes can significantly improve blood sugar control and reduce complications.
❓ When should someone consult a doctor about diabetes?
Consult a healthcare provider if you experience signs of diabetes, have a family history, are overweight, or are over 45. Those with existing diabetes should maintain regular check-ups every 3-6 months to monitor control and adjust treatment as needed.
⚕️ Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.